tirzepatide better than retatrutide vs Tirzepatide: Key Differences for Researchers Retatrutide vs Tirzepatide UK (2026)

(2017, December)

FDA inspections of Empowers facilities from 2022 to 2024 turned up instances in which the company used non-pharmaceutical-grade ingredients for different types of drugs, including the skin treatment azelaic acid, a non-GLP-1 weight loss drug, and the anti-aging drug NAD+, according to two inspection reports

We hope the rowers don't catch a croc

Common side effects reported in clinical literature for GLP-1 receptor agonists include nausea (often most pronounced during dose escalation and the first several weeks of treatment), vomiting, diarrhea, constipation, headache, fatigue, and for injectable forms, injection site reactions

Therapeutic Optionality and Pipeline Catalysts Beyond obesity, the GLP-1 drug class has evolved into a broader platform for metabolic and longevity-related therapies